Yuexin Yu - ANDERA PARTNERS :ANDERA PARTNERS

Yuexin is director at Life Sciences team based in Paris. He has been involved in portfolio companies including Amolyt (acquired by AZ), ReViral (acquired by Pfizer), LogicBio (acquired by Alexion), Mineralys (MLYS), Artios, Evommune, Tubulis, TargED, and JenaValve.
Before joining Andera, Yuexin was at 3H Health Investment Management based in Hong Kong, mainly focusing on investments of biopharma companies headquartered in Asia. He led the investments of InnoCare (HK.9969, SH.688428), KeyMed (HK.2162), RareStone Group, EdiGen, and was involved in the investments of CanSino (HK.6185), HeMo Bioengineering, and Imperative Care.
Prior to VC life, Yuexin was part of the life cycle management teams of Remicade and Keytruda at MSD. He started career at bioMérieux in the corporate venture arm in France, and then business development in the portfolio company Biotheranostics (later acquired by Hologic) in the US.
Yuexin has bachelor’s degree in pharmacy from SJTU and business degree from HEC Paris. He speaks Chinese, English and French.